ArticleNature chemical biology2014
Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.
Article in Nature chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 188 citations in OpenAlex.
- Sulfated polysaccharides target RANK Lys97 to inhibit osteoclast differentiation and reverse osteoporosis.Nature biomedical engineering · 2026Article
- Synthetic biology for heparin biomanufacturing.Bioresources and bioprocessing · 2026Review
- Merging Enzymatic Catalysis with Iron Catalysis for Highly Stereoselective Heparan Sulfate Oligosaccharide Assembly.Journal of the American Chemical Society · 2026Article
- Simple One-Step Deuterated Peracetylation-MALDI-MS/MS (OSDPM) Strategy for Structural Sequencing of Glycosaminoglycan Oligosaccharides.Analytical chemistry · 2025Article
- Efficient Small-Molecule Reversal Agents for Anticoagulant Fondaparinux.ACS pharmacology & translational science · 2025Article
- The effect of ultrasonic-assisted enzymes extraction on antioxidant polysaccharide activity in dandelion.Ultrasonics sonochemistry · 2025Article
- Characterization of Heparin Interactions With Recombinant Rodent Stabilin-2/Hyaluronic Acid Receptor for Endocytosis (HARE).Proteoglycan research · 2025Article
- Editor's Choice Development of a method to measure the activity of heparan sulfate 6-endosulfatase for biological research.Glycobiology · 2025Article
- Comprehensive Coagulation Management in Cardiac Surgery: Anticoagulants, Heparin Resistance, Monitoring, and Bleeding Risks : Coagulation Management in Cardiac Surgery.Galen medical journal · 2025Review
- Structural and Functional Analysis of Heparosan Synthase 2 fromACS catalysis · 2024Article
- Control of tissue homeostasis by the extracellular matrix: Synthetic heparan sulfate as a promising therapeutic for periodontal health and bone regeneration.Periodontology 2000 · 2024Review
- Host heparan sulfate promotes ACE2 super-cluster assembly and enhances SARS-CoV-2-associated syncytium formation.Nature communications · 2023Article
- Article
- Increased 3-Science advances · 2023Article
- Heparan sulfate promotes ACE2 super-cluster assembly to enhance SARS-CoV-2-associated syncytium formation.Research square · 2023Article
- Investigation of the pharmacokinetic properties of synthetic heparan sulfate oligosaccharides.Glycobiology · 2023Article
- Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Heparan sulfates and heparan sulfate binding proteins in sepsis.Frontiers in molecular biosciences · 2023Review
- Design of a biocatalytic cascade for the enzymatic sulfation of unsulfated chondroitin withFrontiers in bioengineering and biotechnology · 2023Article
- Design and Synthesis of Neutralizable Fondaparinux.JACS Au · 2022Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used to treat thrombotic disorders, but impurities, structural heterogeneity or functional irreversibility can limit treatment options. We report a series of synthetic LMWHs prepared by cost-effective chemoenzymatic methods. The high activity of one defined synthetic LMWH against human factor Xa (FXa) was reversible in vitro and in vivo using protamine, demonstrating that synthetically accessible constructs can have a critical role in the next generation of LMWHs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.